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Background. Respiratory syncytial virus (RSV) is the most common viral pathogen associated with acute lower respiratory 
infections (ALRIs), with significant childhood morbidity and mortality worldwide. Estimates reporting RSV-associated ALRI (RSV-
ALRI) severity in children with congenital heart disease (CHD) are lacking, thus warranting the need to summarize the available 
data. We identified relevant studies to summarize the findings and conducted a meta-analysis of available data on RSV-associated 
ALRI hospitalizations in children aged <5 years, comparing those with underlying CHD to those without CHD.
Methods. We conducted a systematic search of existing relevant literature and identified studies reporting hospitalization of 
children aged <5 years with RSV-ALRI with underlying or no CHD. We summarized the data and conducted (where possible) a 
random-effects meta-analysis to compare the 2 groups.
Results. We included 18 studies that met our strict eligibility criteria. The risk of severe RSV-ALRI (odds ratio, 2.2; 95% confi-
dence interval [CI], 1.6–2.8), the rate of hospitalization (incidence rate ratio, 2.8; 95% CI, 1.9–4.1), and the case-fatality ratio (risk 
ratio [RR], 16.5; 95% CI, 13.7–19.8) associated with RSV-ALRI was higher among children with underlying CHD as compared to 
those without no CHD. The risk of admission to the intensive care unit (RR, 3.9; 95% CI, 3.4–4.5), need for supplemental oxygen 
therapy (RR, 3.4; 95% CI, .5–21.1), and need for mechanical ventilation (RR, 4.1; 95% CI, 2.1–8.0) was also higher among children 
with underlying CHD.
Conclusion. This is the most detailed review to show more-severe RSV-ALRI among children aged <5 years with underlying 
CHD, especially hemodynamically significant underlying CHD, as compared those without CHD, supporting a need for improved 
RSV prophylactics and treatments that also have efficacy in children older than 1 year.
Keywords. Respiratory syncytial virus; acute lower respiratory infections; congenital heart disease.
Respiratory syncytial virus (RSV) is the most common viral 
pathogen identified in children with acute lower respiratory 
infections (ALRIs), with significant childhood morbidity and 
mortality worldwide [1–3]. It is estimated that RSV was asso-
ciated with a global burden of 33.1 million cases of ALRI and 
3.4 million admissions in 2015 [4]. There is no specific treat-
ment or vaccine available for RSV infection at the moment, but 
immunoprophylaxis with palivizumab has been available for pre-
vention of RSV infection in high-risk groups since 1998 [5, 6]. The 
high-risk groups include children born prematurely, those with 
bronchopulmonary dysplasia, congenital heart disease (CHD), 
and some immunodeficiency conditions, with higher rates of hos-
pitalization, morbidity, and mortality in all groups [7, 8].
Several studies have demonstrated the severity of RSV disease 
in children with underlying CHD. For example, a higher risk of 
RSV hospitalization (incidence rate ratio [IRR], 1.7; 95% con-
fidence interval [CI], 1.5–2.0 [9]) and a higher risk of intensive 
care unit (ICU) admission (odds ratio [OR], 3.1; 95% CI, 1.1–
8.3 [10]) among children with underlying CHD as compared 
to those without CHD. Palivizumab has been demonstrated 
to reduce RSV hospitalizations among children with hemody-
namically significant underlying CHD by 45% and the length of 
hospital stay (LOS) by up to 76% [11]. There remains, however, 
variation between and within countries regarding the recom-
mendation for the use of palivizumab as prophylaxis for infants 
with underlying CHD [12–14].
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A recent review summarized data on morbidity and mor-
tality of RSV infection among children with CHD [15], but it 
did not include some important studies [1, 7, 16–18] or con-
duct a meta-analysis for the reported outcomes. In our analysis, 
we reviewed the available data and conducted a meta-analysis 
to provide estimates of RSV-ALRI severity among children 
with underlying or no CHD. This will likely generate simpler 
conclusions that are useful for comparative purposes and deci-
sion making.
METHODS
Search Strategy
We systematically searched for existing relevant literature in 
the MEDLINE, EMBASE, and Global Health databases, using 
well-defined search terms (Supplementary Table 1), without 
restrictions on country or time of publication. The search was 
completed on 3 April 2017. Two authors (P. S.  C.  and S.  W. 
L. W.) conducted the literature search and data extraction in-
dependently. Any disagreements were arbitrated by H. N. The 
study was registered with PROSPERO (registration number 
CRD42017060361; available at: https://www.crd.york.ac.uk/
prospero/).
Definition and Selection Criteria
We searched for information on hospitalization data (ie, rates 
and age at admission) among children aged <5 years with RSV-
ALRI with and without  underlying CHD. We also searched 
for information on mortality rate, LOS, need for supplemental 
oxygen therapy, mechanical ventilation, ICU admission, and 
risk of severe RSV-ALRI (which included clinical signs of se-
vere disease, such as apnea, abnormal blood gas levels, LOS 
>5 days, need for supplemental oxygen therapy or mechanical 
ventilation, as defined by the included publications for the 
multivariable analysis) among both groups of children. Studies 
were initially screened by using their titles and abstracts. 
The full texts of the selected studies were then reviewed for 
eligibility.
Publications were eligible for inclusion if they reported data 
on children who were hospitalized with RSV-ALRI, were aged 
<5 years, and reported data on children with both underlying 
as well as CHD (those reporting data only for children without 
CHD were excluded) and if they provided the full text of the 
article in English. Publications were excluded if they involved 
children aged >5 years or did not specify participants’ age; were 
conference abstracts, reviews, or case notes; reported data on 
prophylaxis for, prevention of, and treatment of RSV infection 
without providing specific data for the outcomes of interest for 
underlying CHD; reported data on RSV-ALRI as a coinfection, 
rather than a primary outcome; reported data on CHD as a 
comorbidity or part of a syndrome, rather than a specific un-
derlying disease; and/or provided data on cases of bronchiolitis 
(without laboratory confirmation of RSV-ALRI).
Data Extraction and Analysis
We extracted data by using a standardized data-extraction 
template. For placebo-controlled studies, we used the pla-
cebo arm to extract data. We extracted the means, medians, 
and percentages and measurements of risk. We adopted the 
GRADE method of scoring [19] to assess the quality of the in-
cluded studies (Supplementary Tables 2 and 3) and obtained 
the overall score as an average of the scores from the individual 
studies.
We conducted a meta-analysis of the data by using Stata, 
version 12 (Stata, College Station, TX). We reported risk ratios 
(RRs) for hospitalization and ICU admission rates, the need 
for supplementary oxygen therapy and mechanical ventila-
tion, and the case-fatality ratio (CFR); IRRs for hospitalization 
rates; and ORs for the risk of severe RSV-ALRI. We subdivided 
the incidence rate of hospitalization, by age (0 to <12 months 
and 12 to <24 months), which was not feasible for the other 
variables, and reported the statistical significance of the dif-
ference between the 2 groups. Where age ranges were not 
the same, we summed the narrower age ranges to a common 
broader age range. We reported the median age on admission 
and the LOS descriptively.
Some studies specified underlying CHD as hemodynam-
ically significant, while others did not (Supplementary Table 
4). Thus, for outcomes in which both categories of underlying 
CHD were included (ie, ICU admission, need for mechan-
ical ventilation, and the CFR), we conducted subgroup anal-
ysis and reported the statistical significance of the difference 
between these 2 groups. Subgroup analysis was not feasible 
for the hospitalization rates and oxygen supplementation 
outcomes, as these included only 2 studies each, with under-
lying CHD specified in one and unspecified in the other. For 
the risk of severe RSV-ALRI, all studies included were for 
children with unspecified underlying CHD and thus needed 
no further restratification. Cases of underlying CHD were not 
reclassified as cyanotic or acyanotic for meta-analysis, owing to 
limited data. We used a random-effects model to obtain sum-
mary estimates and reported the 95% CIs where applicable. We 
used the Egger test to assess funnel plot asymmetry as evidence 
for publication bias, where applicable (ie, for ICU admissions, 
need for mechanical ventilation, and CFR). Statistical signifi-
cance was set at a P value of <.05.
RESULTS
We included 18 studies in the review, following the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) protocol (Supplementary Figure 1 and 
Supplementary Table 5). The overall quality of the studies was of 
medium grade (average score, 3.6 of 8.0; Supplementary Tables 
2 and 3); 5 were of low quality (score, <2.5), 12 were of moderate 
quality (score, 2.5 to ≤5.0), and 1 was of high quality (score, >5.0 
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to 8.0). Only for oxygen supplementation (I2 of 97%; P < .001) 
and mechanical ventilation (I2 of 94%; P < .001) was evidence 
of significant heterogeneity observed. There was no evidence of 
publication bias for the tested outcomes: P = .32 for ICU admis-
sion, P = .75 for mechanical ventilation, and P = .88 for CFR.
Hospitalization Rates
Two studies reported hospitalization rates per 1000 children 
[20, 21]. Because one included children aged <24 months [21] 
and the other included children aged <36 months [20], we di-
vided the results into 2 subgroups by age (0 to <12 months and 
12 to <24 months), to combine the 2 studies. Overall, children 
aged 0–24 months with underlying CHD had a 2.8-fold (95% 
CI, 1.9–4.1-fold) higher risk of hospitalization than children 
without CHD (Supplementary Figure 2). Among children 
aged 0 to <12 months, the mean hospitalization rate was 102.5 
events/1000 children for those with underlying CHD and 35.2 
events/1000 children for those with no CHD (IRR, 2.5; 95% 
CI, 1.4–4.5); among those aged 12 to <24 months, rates were 
11.5 events/1000 children and 3.0 events/1000 children, re-
spectively (IRR 3.8, 95% CI, 1.5–9.3). Difference in the risk 
of hospitalization between the 2 age groups was not statisti-
cally significant (P =  .46). Boyce et al reported a hospitaliza-
tion rate of 4.8 events/1000 children with underlying CHD and 
1 event/1000 children without CHD among those aged 24 to 
<36 months [20]. Two population-based studies reported the 
proportion of hospitalizations among children with underlying 
CHD and those without CHD [21, 23], rather than providing 
incidence rates per 1000 children, with an RR of 3.7 (95% CI, 
1.5–9.0) for the group with underlying CHD group, using the 
group without CHD as a reference. Four studies reported the 
proportion of hospitalizations for children with underlying 
CHD but not for those without CHD, Andres et al reported a 
proportion of 21.1% (15 children) [16] and Feltes et al reported 
a proportion of 9.7% (63 children) [11] among participants 
with hemodynamically significant underlying CHD, whereas 
MacDonald et al reported a proportion of 37.0% (27 children) 
[8] and Saji et al reported a proportion of 0.9% (83 children, all 
in the placebo group) [18] among participants with unspeci-
fied underlying CHD.
Median Age on Admission and LOS
Two studies reported the median age in months on admission 
and the LOS, only for children aged <24 months. Median ages 
were 5.7 months (range, 2.1–19.4 months) for children with un-
derlying CHD versus 4.3 months (range, 1.1–23.6 months) for 
those without CHD in one study [21] and 7.0 months (range, 
0–23.0  months) versus 6.0  months (range, 0–23.0  months) 
[24], respectively, in the other. The median LOS was 6.5 days 
(range, 2.0–41.0 days) for children with underlying CHD and 
5.0 days (range, 1.0–30.0 days) for those without CHD in the 
study by Duppenthaler et al [21], with values of 6.0 days (range, 
2.0–14.0 days) and 4.0 days (range, 1.0–41.0 days), respectively, 
in the article by Fjaerli et al [24].
ICU Admissions
Five studies provided data on ICU admissions [8, 21, 22, 23, 
26]. Children with underlying CHD had a 3.9-fold (95% CI, 
3.4–4.5-fold) higher risk of ICU admission as compared to 
those without CHD (Supplementary Figure 3). Upon further 
stratification, children with hemodynamically significant CHD 
had a 5.0-fold (95% CI, 2.9–8.9-fold) higher risk and those with 
unspecified CHD had a 3.9-fold (95% CI, 3.3–4.5-fold) higher 
risk, compared with children without CHD. The difference in 
risk between the hemodynamically significant CHD group and 
the unspecified CHD group was not significant (P = .37). Two 
studies provided data on the proportion of hospitalized hemo-
dynamically significant CHD RSV cases that required ICU ad-
mission, with values of 40% (6 of 15 children) [16] and 38.1% 
(24 of 63 children) [11].
Oxygen Supplementation
Two studies reported data on the need for supplemental oxygen 
therapy. Children with underlying CHD had a 3.4-fold (95% CI, 
.5–21.1-fold) higher risk of requiring oxygen supplementation, 
compared with those without CHD (Supplementary Figure 
4) [7, 21]. One study reported the median duration of oxygen 
supplementation, with values of 5 days (range, 1–34 days) for 
children with underlying CHD and 2 days (range, 0–26 days) 
for children without CHD [21].
Mechanical Ventilation
Seven publications reported data on the need for mechanical 
ventilation (Supplementary Figure 5) [7, 8, 13, 21, 22, 17, 27]. 
Only 1 study reclassified underlying CHD cases as cyanotic 
or acyanotic, and all 6 recorded cases were acyanotic [13]. 
Overall, children with underlying CHD had a 4.1-fold (95% CI, 
2.1–8.0-fold) higher risk of needing mechanical ventilation as 
compared to those without CHD. By subgroup, children with 
hemodynamically significant underlying CHD had a 4.8-fold 
(95% CI, 4.6–5.1-fold) higher risk and those with unspecified 
underlying CHD had a 3.4-fold (95% CI, 1.1–11.0-fold) higher 
risk of needing mechanical ventilation, compared with children 
without CHD. The difference in risk between the hemody-
namically significant CHD group and the unspecified CHD 
group was not significant (P = .56). One study that included 
only children with unspecified underlying CHD reported that 
19.3% of children (16 of 83; all in the placebo group) required 
mechanical ventilation [18]. Two others provided data only on 
children with hemodynamically significant underlying CHD, 
with 5 children (33.0%) [16] and 14 children (22.2%) [11] 
needing mechanical ventilation. Only one study reported on the 
duration of mechanical ventilation, with a mean difference of 
11.3 days between children with unspecified underlying CHD 
and those without CHD [13].
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Risk of Severe RSV-ALRI
Three studies reported unspecified underlying CHD as a risk 
factor for severe RSV-ALRI, using multivariable analysis (other 
variables included were clinical signs of severe disease, such as 
apnea, abnormal blood gas levels, LOS >5 days, need for supple-
mental oxygen therapy, and need for mechanical ventilation). 
Rodriguez et al reported an RR of 2.0 (95% CI, 1.2–3.5) [28], 
Kaneko et al reported an OR of 99.2 (95% CI, 8.5-1160.1) [7], 
and Zhang et al reported an OR of 2.3 (95% CI, 1.7–3.1) [1]. By 
assuming that the RR of 2.0 reported by Rodriguez et al [28] is 
equivalent to the OR (because severe RSV-ALRI with under-
lying CHD is rare), we conducted a meta-analysis of these ORs 
and obtained an OR of 2.2 (95% CI, 1.6–2.8).
Risk of RSV-ALRI–Associated Death
Eight studies reported mortality data (Table 1). We observed 
a higher overall CFR among those with underlying CHD as 
compared to those without CHD [8, 21, 22, 17, 27]. Two studies 
reported a lower CFR among children with unspecified under-
lying CHD as compared to those without CHD [12, 28], while 
1 study reported no death in either group [7]. Children with 
underlying CHD had a 16.5-fold (95% CI, 13.7–19.8-fold) 
higher risk of RSV-ALRI–associated death overall, compared 
with children without CHD. By subgroup, those with hemody-
namically significant underlying CHD had a 17.9-fold (95% CI, 
14.9–21.6-fold) higher risk, whereas the group with unspecified 
underlying CHD had a 9.6-fold (95% CI, 8.9–10.4-fold) higher 
risk, compared with the group without CHD. The difference in 
risk between the hemodynamically significant CHD group and 
the unspecified CHD group was not significant (P = .22).
DISCUSSION
Our review demonstrated that the severity of RSV-ALRI was 
higher among children with underlying CHD as compared to 
those without CHD, especially with regard to the need for hos-
pitalization, intensive care management, respiratory support, 
and that underlying CHD was associated with an increased 
CFR, compared with no CHD.
The higher risk for hospitalization in the group with under-
lying CHD could be due to higher severity of the disease in 
children with underlying CHD or a result of physician behavior 
when deciding whether to admit those with perceived risk 
factors. We also found that the age-related risk of hospitaliza-
tion for RSV-ALRI among children with underlying CHD was 
more widely distributed as compared to that among children 
without CHD, similar to findings from an earlier publication, 
which reported a mean age (±SD) of 6.3 ± 6.0 months among 
admitted patients with underlying CHD, compared with 3.5 ± 
3.3 months in the healthy group [29].
Risks for all the measured outcomes were higher in the group 
with underlying CHD, compared with the non-CHD group. 
High rates of hospitalization, ICU admission, and death among 
children with RSV-LRTI and underlying CHD were also re-
ported by other studies, but they did not fulfill the criteria for 
inclusion in our review [30, 31]. Sensitivity analysis revealed a 
higher effect among cases of hemodynamically significant un-
derlying CHD, compared with cases of unspecified underlying 
CHD. Although the small sample size in some of the studies 
could have affected the statistical significance of findings, these 
data suggest that the severity of RSV-ALRI displayed a trend 
toward a positive association with the severity of underlying 
CHD. The higher severity of RSV-ALRI in the group with un-
derlying CHD could have severe long-term implications on the 
children’s health and the cost of their care. In addition, RSV 
infection may delay cardiac surgery, and during the convales-
cence phase there is an increased risk of a more severe disease 
outcome and possible long-term complications [30, 32, 33]. 
Because underlying CHD has been associated with increased 
RSV-ALRI severity, such a group will be a useful target for pre-
ventive measures.
Despite the availability of palivizumab for 
immunoprophylaxis, there are significant differences in the 
guidelines for its use, such as those from the French Society 
of Cardiology [34] and the American Academy of Pediatrics 
(AAP) [12, 13]. These differences could be a challenge in 
formulating a standard universal protocol for palivizumab use. 
The updated AAP recommendation for the use of palivizumab 
in children with hemodynamically significant CHD still 
includes only children aged <1 year [35] and is probably based 
on the finding by Boyce et  al that the rate of RSV-associated 
hospitalization among children with CHD aged >1  year was 
not higher than that among low-risk children [20]. However, 
other outcome measurements that could define the severity of 
RSV-ALRI among hospitalized children, such as the need for 
ICU admission, supplemental oxygen therapy, mechanical ven-
tilation, or the risk of RSV-ALRI–associated death, were not 
assessed in this study. Thus, hospitalized children with hemo-
dynamically significant underlying CHD may have a more se-
vere disease progression as compared to those without CHD, 
as shown in our review, in which the rate of RSV-ALRI–asso-
ciated hospitalization was higher among children in the second 
year of life as compared to those in the first year. Furthermore, 
the international multicenter randomized controlled trial that 
demonstrated benefits of palivizumab prophylaxis in children 
with hemodynamically significant underlying CHD, including 
a decrease in the RSV-associated hospitalization rate and the 
duration of supplemental oxygen supplementation therapy in 
this group as compared to the placebo group (with a greater 
decrease among children with acyanotic hemodynamically sig-
nificant CHD than among with cyanotic hemodynamically sig-
nificant underlying CHD), included children up to 24 months of 
age [11, 36]. Considering that the study lasted up to 4 years, with 
benefits recorded throughout this period, the beneficial effect 
of palivizumab prophylaxis in children with hemodynamically 
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significant underlying CHD may go even beyond 2  years of 
age. Other professional societies include children aged <2 years 
under certain conditions in their recommendations, such as 
those in France and Germany and, more recently, an interna-
tional committee of experts, whereas the British Congenital 
Cardiac Association and Joint Committee on Vaccination and 
Immunization guidelines also include children older than 
1  year with complex heart disease in their recommendation 
for immunoprophylaxis based on clinical judgment [37]. With 
improvement in cardiac surgical care, those with underlying 
CHD who are older than 1 year of age may increasingly repre-
sent the more severe spectrum of underlying CHD for whom 
immunoprophylaxis may be of greatest benefit.
This report has several strengths and limitations. We have in-
cluded studies from North America, South America, Europe, 
and Asia but none from Africa. This limitation and the hetero-
geneity of the data make generalization of the results difficult. 
The limited data on certain outcomes, such as duration of sup-
plemental oxygen therapy, made it difficult to synthesize the 
data for such outcomes and were therefore only reported de-
scriptively. There was no standard case definition of RSV-ALRI 
infection, underlying CHD, or hemodynamically significant 
underlying CHD. Other underlying conditions (eg, prematu-
rity) that may have biased outcome measurements were not 
highlighted by some of the studies. Most of the included studies 
were retrospective studies, from which evidence is less strong. 
These factors and the lack of proper matching affected the 
quality of the studies (medium grade overall).
There were scarce data available for children with underlying 
CHD aged >24 months, thus limiting the conclusions that may 
be drawn for those who are 2–4 years of age with underlying 
CHD. Additional data are required on the effects of RSV-ALRI 
in this population, both before and after cardiac surgery, before 
the effects of RSV infection on corrective cardiac surgery can be 
assessed in a meta-analysis.
Only 6 of 18 included studies specified the underlying 
CHD cases as hemodynamically significant, and only 1 study 
reclassified the cases of underlying CHD (unspecified) into cya-
notic and acyanotic, albeit just for 1 outcome (need for mechan-
ical ventilation) [13]. Thus, subgroup analysis based on cyanotic 
and acyanotic criteria was not feasible. Although all included 
cases that required mechanical ventilation were acyanotic and 
because the benefits of palivizumab prophylaxis in children 
with hemodynamically significant underlying CHD are shown 
to be higher in this group (as mentioned earlier), we did not 
have enough evidence to prove this.
In summary, children with RSV with underlying CHD, es-
pecially hemodynamically significant underlying CHD, have 
more severe RSV-ALRIs than those without CHD. Our analysis 
identifies an unmet requirement for preventive therapies and 
treatments to reduce the high risk of morbidity and mortality 
associated with RSV infection in those with underlying CHD. 
The introduction and acceptance of a standardized disease clas-
sification for underlying CHD and hemodynamically signifi-
cant underlying CHD would enable proper case definition, thus 
enhancing the feasibility and comparability of investigational 
studies of preventive therapies and treatments. Furthermore, 
recommendations and application of preventive and treatment 
guidelines for underlying CHD should include older children, 
because the risk of higher morbidity and mortality is not lim-
ited to children aged <1 year.
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